[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"customer-session":3,"post:bpc-157-tb-500-blend-reconstitution-and-concentration-reference-for-research":5},{"loggedIn":4},false,{"id":6,"slug":7,"title":8,"content":9,"excerpt":10,"path":11,"modified":12,"featuredImage":13,"seo":17,"date":20,"author":18,"categories":21,"readingMinutes":28},41718,"bpc-157-tb-500-blend-reconstitution-and-concentration-reference-for-research","BPC-157 + TB-500 Blend: Reconstitution and Concentration Reference for Research","\u003Cp>\u003Cspan style=\"font-weight: 400;\">By \u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fveloraresearch.com\u002Fauthor\u002Fclarkjones\u002F\">\u003Cspan style=\"font-weight: 400;\">Clark Jones, PhD\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan style=\"font-weight: 400;\">, Velora Research \u003C\u002Fspan>\u003Ci>\u003Cspan style=\"font-weight: 400;\">Written and reviewed for scientific accuracy by Clark Jones, PhD ([ORCID 0009-0005-9356-0297](https:\u002F\u002Forcid.org\u002F0009-0005-9356-0297)). Last reviewed 2026-05-28.\u003C\u002Fspan>\u003C\u002Fi>\u003C\u002Fp>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cb>Quick answer:\u003C\u002Fb>\u003Cspan style=\"font-weight: 400;\"> BPC-157 and thymosin beta-4 fragment (TB-500) are two short peptides that show up together a lot in preclinical tissue-repair literature, which is why several research vendors supply them as a co-formulated vial. A common Velora “Wolverine Blend” format is 5 mg BPC-157 plus 5 mg TB-500 in one vial. Reconstituted in 2 mL of bacteriostatic water, that gives you 2.5 mg\u002FmL of each peptide and a combined 5 mg\u002FmL of peptide content. The math, the chemistry, and the research framing are all below.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Ch2>\u003Cb>Research use only: what this article is, and what it isn’t\u003C\u002Fb>\u003C\u002Fh2>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">This article is a benchwork reference for researchers handling a co-formulated BPC-157 and TB-500 vial in vitro or in preclinical models. It is not medical advice, prescribing guidance, or a recommendation for human use of either peptide individually or together.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">Neither BPC-157 nor TB-500 is approved by the U.S. Food and Drug Administration, the European Medicines Agency, or any other national regulator for any indication. The “Wolverine Blend” research product supplied by Velora Research is sold strictly for laboratory research use, not for human consumption, veterinary use, or in vivo use in any species. The phrase “Wolverine Blend” is a product name; researchers should not read it as a claim of regenerative capability in any subject.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">Concentrations and routes referenced below are drawn from peer-reviewed preclinical literature on each peptide individually. They are documented for research orientation, not as a co-administration protocol. Researchers are responsible for compliance with all applicable law, including the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 331, § 355, § 360bbb-3), and institutional review requirements.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Ch2>\u003Cb>What BPC-157 is\u003C\u002Fb>\u003C\u002Fh2>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">BPC-157 is a synthetic pentadecapeptide, fifteen amino acids long, originally derived from a partial sequence of a larger protein identified in human gastric juice (the body-protection compound, or BPC). Most of the published preclinical work on BPC-157 originates from the Sikiric group at the University of Zagreb, accumulated across more than two decades of rodent studies examining gastric, musculoskeletal, and vascular endpoints \u003C\u002Fspan>\u003Cspan style=\"font-weight: 400;\">(\u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F29879879\u002F\" target=\"_blank\" rel=\"noopener\">\u003Cspan style=\"font-weight: 400;\">P. Sikiric et al., 2006 PMC review on BPC-157 pharmacology\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan style=\"font-weight: 400;\">).\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">In those preclinical models, BPC-157 has been associated with effects on angiogenesis, on growth-factor expression including VEGF and FGF, and on the nitric oxide system. The molecular weight is approximately 1,419 daltons, which is small for a peptide drug and is part of why BPC-157 is studied across a broad range of administration routes in rodent work.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">It is worth being precise about one thing: the vast majority of the BPC-157 literature is preclinical. Human clinical data is limited. That is the honest research framing.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Ch2>\u003Cb>What TB-500 is\u003C\u002Fb>\u003C\u002Fh2>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">TB-500 is a research designation generally used for synthetic peptide derivatives modeled after the actin-binding region of thymosin beta-4. The exact sequence supplied under the name TB-500 varies among commercial vendors and published reports, making sequence verification important when comparing studies. The full thymosin beta-4 molecule has been studied for its role in cell migration, angiogenesis, and wound repair (\u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F22074294\u002F\" target=\"_blank\" rel=\"noopener\">\u003Cspan style=\"font-weight: 400;\">Goldstein et al., Expert Opinion on Biological Therapy, 2012\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan style=\"font-weight: 400;\">).\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">In preclinical models, the proposed mechanism most often discussed centers on actin sequestration. By binding G-actin, thymosin beta-4 helps regulate the available pool of monomeric actin that cells draw on for cytoskeletal remodeling, which is part of how cells migrate during wound repair. The Velora TB-500 fragment is approximately 889 daltons (per Velora product-page specifications for their fragment; longer 17-amino-acid thymosin beta-4 fragments in the literature are heavier). Depending on the specific synthetic fragment supplied, reported molecular weights vary. Researchers should rely on the molecular weight listed on the batch-specific Certificate of Analysis. \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">Worth flagging again: the published research on TB-500 specifically, as distinct from full thymosin beta-4, is thinner than the BPC-157 literature. Researchers should know what the fragment is and what it is not before designing comparisons.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Ch2>\u003Cb>Why these two get studied together\u003C\u002Fb>\u003C\u002Fh2>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">The short answer is that the preclinical literature on each peptide individually points at overlapping but distinct elements of the wound-repair toolkit: BPC-157 has been associated with angiogenesis and growth-factor signaling, while thymosin beta-4 fragments have been associated with cell migration. The implicit question behind co-administration research is whether the two effects compose additively or synergistically in models of tissue repair. The current literature does not answer that question definitively. Most of what exists is single-peptide work; co-administration studies remain a relatively small subset.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">A practical note for benchwork: co-formulating two peptides in one vial is a vendor convenience, not a pharmacological assertion. If you are designing a controlled experiment, the cleaner design is usually two separate vials with matched-volume vehicle controls.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Ch2>\u003Cb>Reconstitution math for a 5 mg \u002F 5 mg blend\u003C\u002Fb>\u003C\u002Fh2>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">For a Wolverine Blend vial labeled 5 mg BPC-157 + 5 mg TB-500 (10 mg total peptide), the reconstitution math is straightforward. Use bacteriostatic water (BAC water) for any vial you intend to access more than once, since the 0.9% benzyl alcohol acts as a preservative across the in-use window.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Ctable>\n\u003Cthead>\n\u003Ctr>\n\u003Cth>\u003Cb>BAC water volume\u003C\u002Fb>\u003C\u002Fth>\n\u003Cth>\u003Cb>BPC-157 concentration\u003C\u002Fb>\u003C\u002Fth>\n\u003Cth>\u003Cb>TB-500 concentration\u003C\u002Fb>\u003C\u002Fth>\n\u003Cth>\u003Cb>Combined peptide content\u003C\u002Fb>\u003C\u002Fth>\n\u003C\u002Ftr>\n\u003C\u002Fthead>\n\u003Ctbody>\n\u003Ctr>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">1.0 mL\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">5.0 mg\u002FmL (~3.52 mM)\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">5.0 mg\u002FmL (~2.64 mM)\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">10.0 mg\u002FmL\u003C\u002Fspan>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">2.0 mL\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">2.5 mg\u002FmL (~1.76 mM)\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">2.5 mg\u002FmL (~1.32 mM)\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">5.0 mg\u002FmL\u003C\u002Fspan>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">4.0 mL\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">1.25 mg\u002FmL (~0.88 mM)\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">1.25 mg\u002FmL (~0.66 mM)\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">2.5 mg\u002FmL\u003C\u002Fspan>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003C\u002Ftbody>\n\u003C\u002Ftable>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">Molar values assume approximate molecular weights of 1,419 Da for BPC-157 and 889 Da for the TB-500 fragment per Velora product-page specifications. If your protocol calls for working concentrations in the low-micromolar range typical of cell-based assays, the stock will need serial dilution in your assay buffer; a 5 mg\u002FmL of each at a 1:1,000 dilution in buffer gives you approximately 1.76 µM BPC-157 and 1.32 µM TB-500.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">The reconstitution itself follows the standard slow-stream technique: add diluent against the inner glass wall of the vial, swirl gently for 30 to 60 seconds until the lyophilized cake is fully dissolved, and do not shake. Label the vial with the date and the final concentrations of each peptide in both mg\u002FmL and mM.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Ch2>\u003Cb>Routes used in published research\u003C\u002Fb>\u003C\u002Fh2>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">Both peptides have been studied across multiple administration routes in animal models. In rodent work, subcutaneous administration is the route most commonly used for both compounds in published mechanistic studies. Intraperitoneal administration is also reported, particularly in earlier BPC-157 work. Topical application appears in some in-vitro and ex-vivo skin-and-tendon repair models. Each route is a research-design choice in an animal or cell model, not a translation to any human or veterinary use.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">Published pharmacokinetic data for both peptides remain limited. Available animal studies suggest relatively short circulating persistence for the parent compounds, although reported values vary substantially depending on study design , analytical method, and peptide formulation. The thymosin beta-4 fragment literature is less well-characterized on pharmacokinetic parameters than the full protein, and that gap is worth noting in any methods section that cites it.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Ch2>\u003Cb>Storage and stability\u003C\u002Fb>\u003C\u002Fh2>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">The lyophilized blend is stable for extended periods at -20°C. Common current practice in other research laboratories is to store the reconstituted working stock at 2 to 8°C, protected from light, and use it within roughly 28 to 30 days; Velora has not published stability studies on the reconstituted product, so this window should be treated as a laboratory convention rather than a validated shelf life with many labs that limit bacteriostatic water reconstitution to about one month, although peptide-specific stability depends on formulation and has not been comprehensively established for either compound. Sterile water reconstitutions, without a preservative, are much shorter-lived and are usually treated as single-use.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">Do not freeze-thaw reconstituted material. The aggregation and denaturation that follow repeated freeze-thaw cycles will degrade both peptides, and unlike the lyophilized state, the damage is not reversible.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">“Both of these peptides are small, both are reasonably soluble in BAC water, and both have well-behaved chemistry on a clean reconstitution. The thing that will hurt your results is not the math, it’s the COA. If you don’t know your peptide content by HPLC and your identity by mass spec, you don’t really know what you’re studying.”\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">Clark Jones, PhD, Velora Research\u003C\u002Fspan>\u003C\u002Fp>\n\u003Ch2>\u003Cb>Working with verified material\u003C\u002Fb>\u003C\u002Fh2>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">Velora’s \u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fveloraresearch.com\u002Fproduct\u002Fwolverine-blend-tb-500-bpc-157-5mg-5mg\u002F\">\u003Cspan style=\"font-weight: 400;\">Wolverine Blend 5 mg + 5 mg\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan style=\"font-weight: 400;\"> ships with a third-party Certificate of Analysis. The COA covers identity by mass spec, purity by HPLC at ≥99% per peptide, water content by Karl Fischer, and endotoxin by LAL. Each batch is independently traceable. The same release protocol applies across the rest of the \u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fveloraresearch.com\u002Fproduct-category\u002Fpeptides\u002F\">\u003Cspan style=\"font-weight: 400;\">research peptide catalog\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan style=\"font-weight: 400;\">, and \u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fveloraresearch.com\u002Fabout-us\u002F\">\u003Cspan style=\"font-weight: 400;\">Velora’s quality and testing process\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan style=\"font-weight: 400;\"> is documented end to end.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">The reason to care about this on a blended product specifically: a co-formulated vial that reports only “total peptide content” instead of per-peptide purity is a methods-section liability. Two peptides, each independently quantified, is the standard that makes a research result reproducible.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Ch2>\u003Cb>Frequently asked questions\u003C\u002Fb>\u003C\u002Fh2>\n\u003Cp>\u003Cb>Is BPC-157 FDA-approved?\u003C\u002Fb>\u003Cspan style=\"font-weight: 400;\"> No. BPC-157 is not approved by the FDA or any other national regulator for any indication. The vast majority of the published research is preclinical.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cb>Is TB-500 the same molecule as thymosin beta-4?\u003C\u002Fb>\u003Cspan style=\"font-weight: 400;\"> TB-500 is generally used in research catalogs to refer to the active fragment of thymosin beta-4 containing the actin-binding domain, not the full 43-amino-acid protein. Some literature uses the names interchangeably, so when you cite a study, check which molecule the authors actually used.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cb>Why are they sold as a blend?\u003C\u002Fb>\u003Cspan style=\"font-weight: 400;\"> Because the preclinical literature on each individually points at overlapping wound-repair pathways, and a single vial is operationally simpler for research that wants to compare a co-administered condition to a single-peptide condition. Co-formulation is a vendor convenience, not a pharmacological claim about additive effect.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cb>How should the blend be stored after reconstitution?\u003C\u002Fb>\u003Cspan style=\"font-weight: 400;\"> At 2 to 8°C, protected from light, in the original vial. Use within approximately 28 to 30 days if reconstituted in bacteriostatic water. Do not freeze.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cb>Can the two peptides be quantified separately on a COA?\u003C\u002Fb>\u003Cspan style=\"font-weight: 400;\"> Yes, and they should be. A reputable third-party COA on a blend will report identity and purity for each peptide independently, not just a combined peptide content. If you only see a total, ask for the per-peptide analysis.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cb>What is the molecular weight of each peptide?\u003C\u002Fb>\u003Cspan style=\"font-weight: 400;\"> Approximately 1,419 daltons for BPC-157 and approximately 889 daltons for this TB-500 fragment. Use those values when you calculate molar concentrations from a gravimetric stock.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Ch2>\u003Cb>Sources and further reading\u003C\u002Fb>\u003C\u002Fh2>\n\u003Cul>\n\u003Cli style=\"font-weight: 400;\" aria-level=\"1\">\u003Cspan style=\"font-weight: 400;\">Sikiric P, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. \u003C\u002Fspan>\u003Ci>\u003Cspan style=\"font-weight: 400;\">Current Pharmaceutical Design\u003C\u002Fspan>\u003C\u002Fi>\u003Cspan style=\"font-weight: 400;\">. 2011. \u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F21548867\u002F\" target=\"_blank\" rel=\"noopener\">\u003Cspan style=\"font-weight: 400;\">PubMed\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fli>\n\u003Cli style=\"font-weight: 400;\" aria-level=\"1\">\u003Cspan style=\"font-weight: 400;\">Sikiric P, et al. BPC 157 and Standard Angiogenic Growth Factors. \u003C\u002Fspan>\u003Ci>\u003Cspan style=\"font-weight: 400;\">Frontiers in Pharmacology \u002F PMC review\u003C\u002Fspan>\u003C\u002Fi>\u003Cspan style=\"font-weight: 400;\">. \u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC9159534\u002F\" target=\"_blank\" rel=\"noopener\">\u003Cspan style=\"font-weight: 400;\">PMC\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fli>\n\u003Cli style=\"font-weight: 400;\" aria-level=\"1\">\u003Cspan style=\"font-weight: 400;\">Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. \u003C\u002Fspan>\u003Ci>\u003Cspan style=\"font-weight: 400;\">Expert Opinion on Biological Therapy\u003C\u002Fspan>\u003C\u002Fi>\u003Cspan style=\"font-weight: 400;\">. 2012. \u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fnyaspubs.onlinelibrary.wiley.com\u002Fdoi\u002F10.1111\u002Fj.1749-6632.2012.06796.x\" target=\"_blank\" rel=\"noopener\">\u003Cspan style=\"font-weight: 400;\">Full text\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fli>\n\u003Cli style=\"font-weight: 400;\" aria-level=\"1\">\u003Cspan style=\"font-weight: 400;\">Crockford D, et al. Thymosin beta 4: structure, function, and biological properties supporting current and future clinical applications. \u003C\u002Fspan>\u003Ci>\u003Cspan style=\"font-weight: 400;\">Annals NYAS\u003C\u002Fspan>\u003C\u002Fi>\u003Cspan style=\"font-weight: 400;\">. 2010. \u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F20536467\u002F\" target=\"_blank\" rel=\"noopener\">\u003Cspan style=\"font-weight: 400;\">PubMed\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fli>\n\u003C\u002Ful>\n","By Clark Jones, PhD, Velora Research Written and reviewed for scientific accuracy by Clark Jones, PhD ([ORCID 0009-0005-9356-0297](https:\u002F\u002Forcid.org\u002F0009-0005-9356-0297)). Last reviewed 2026-05-28.…","\u002Fblogs\u002Fbpc-157-tb-500-blend-reconstitution-and-concentration-reference-for-research","2026-07-14T17:25:40",{"src":14,"alt":8,"width":15,"height":16},"https:\u002F\u002Fveloraresearch.com\u002Fwp-content\u002Fuploads\u002F2026\u002F07\u002FBPC-157-TB-500-Blend-Reconstitution-and-Concentration-Reference-for-Research.jpeg",1376,768,{"title":18,"description":19,"canonical":18,"ogTitle":18,"ogDescription":19,"ogImage":14,"robots":18},null,"By Clark Jones, PhD, Velora Research Written and reviewed for scientific accuracy by Clark Jones, PhD ([ORCID 0009-0005-9356-0297](https:\u002F\u002Forcid.org\u002F0009-000…","2026-07-14T17:23:57",[22,25],{"name":23,"slug":24},"Blogs","blogs",{"name":26,"slug":27},"Research & Education","research-education",8]